Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Frontiers in Pharmacology|July 5, 2021
Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin's DiseaseFlorian Lüke, Dennis C Harrer, Karin Menhart, et al.
Melanoma Research|November 10, 2007
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trialAlbrecht Reichle, Thomas Vogt, Brigitte Coras, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|August 12, 2015
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory NeoplasiaChristina Hart, Martin Vogelhuber, Daniel Wolff, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2010
Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroidsEva Gottfried, Sebastian Rogenhofer, Heidi Waibel, et al.
Frontiers in Pharmacology|December 15, 2018
Clinical Efficacy of a Novel Therapeutic Principle, AnakoinosisDaniel Heudobler, Michael Rechenmacher, Florian Lüke, et al.
PPAR Research|July 30, 2009
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant MelanomaStefanie Meyer, Thomas Vogt, Michael Landthaler, et al.
Journal of Hematology & Oncology|July 16, 2014
Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patientsIsabelle Bartram, Nicola Gökbuget, Cornelia Schlee, et al.
Molecular & Cellular Proteomics : MCP|December 3, 2017
Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemiaRupert L Mayer, Josef D Schwarzmeier, Marlene C Gerner, et al.
Leukemia & Lymphoma|July 4, 2020
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Gerhard Zugmaier, Hervé Dombret, et al.
Blood|October 21, 2015
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatmentGerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, et al.
Pageof 8